HP selects Kayentis as Solutions Business Partner for the Healthcare and Life Science Industries
Hewlett-Packard selects Kayentis, a global provider of Digital Pen and Paper technology, as Worldwide Solutions business partner for the health care and life science industries.
HP selects Kayentis as Solutions Business Partner for the Healthcare and Life Science industries
Hewlett-Packard selects Kayentis, a global leader of Digital Pen and Paper technology, as Worldwide Solutions Business Partner for the Healthcare and Life Science industries.
Philadelphia, PA / Gif sur Yvette, France — September 23, 2008
Members of the HP Solutions Business Partner program are selected for geographical reach, business stability, professional services, and support capability.
Kayentis, who has offices both in the US and in Europe and offers “the unique paper-based e-trial solution”, corresponds completely to HP’s high requirements. Clin’form®, its solution dedicated to the clinical trials industry, combines the best of what the physical and the digital world have to offer: the easiest data collection method for both patients and physicians (pen & paper), offering the highest quality of data, combined with all the advantages of electronic data management (accurate timestamps, audit trail functionalities, real-time access, alerts, etc.).
“I am very excited about the partnership between HP and Kayentis,” says Tab Edwards, HP Market Development Consultant. “The combination of HP’s broad portfolio of hardware, software and services, along with the Kayentis Digital Pen and Paper-based solutions, makes for a powerful combination of innovative companies to address the strategic needs of our customers.”
The Digital Pen and Paper (DPP) market is expanding on a worldwide scale. According to Infotrends/CAP Ventures, more than 150 billion paper forms are used globally by enterprises on an annual basis. In many different markets, a lot of companies are still using paper and pen as their main interface to capture data. DPP offers is a high-tech solution adapted to an ancestral way of gathering information.
“HP was, alongside with Anoto, at the origin of the deployment of the Digital Pen and Paper technology, so it is logical that we developed over time special commercial and operational relationship” adds Guillaume Juge, General Manager of Kayentis. “There is a tremendous market potential for our solution. We are working today with international pharmaceutical laboratories, biotechs, CRO, for whom we deployed our solution in more than 50 clinical studies in 40 different countries (including emerging countries like India, Mexico, Tunisia...). This partnership with HP allows us to conquer the US and European Life Science market with solutions which cover our customer needs at each stage of the drug life cycle: R&D, Pre-Clinical, Clinical, Post-Market and Sales. “
“Our technology is particularly meaningful in the clinical research arena, as we are the first company with large global experience to offer what we call: ‘paper-based e-trials’,” says Philippe Berna, CEO of Kayentis. By sharing our expertise with the HP team we will provide our customers a full and globally validated solution including high-quality support and logistics. That partnership is definitely accelerating our international expansion in the USA and Europe.”
ABOUT KAYENTIS
Kayentis is the leading provider of Digital Pen & Paper (DPP) solutions for the clinical trial industry. Built on the Forms Automation System (FAS) architecture, and Anoto technology, the Clin’Form® solution allows for all data written using a digital pen and paper to be recorded in an information system and shared via a secure web portal. This cutting-edge solution combines the ease of use of paper with the high technology tools offered by the digital world. Kayentis is Anoto Platinum partner.
To discover more about this unique solution please visit www.kayentis.com.
ABOUT HP
HP is a technology solutions provider to consumers, businesses and institutions globally. HP is among the world's largest IT companies with a portfolio that spans printing, personal computing, software, services and IT infrastructure.
More information about HP (NYSE, Nasdaq: HPQ) is available at www.hp.com.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.
